As US measles cases rise, biotech firms start developing new treatments
摘要
近期美国麻疹病例数创35年新高，疫苗接种率持续下降。在此背景下，部分生物技术公司和学术团队开始研发针对麻疹感染者的治疗药物，以及为易感人群提供短期保护的疗法。此前因疫苗效果显著，相关治疗手段缺乏研发动力。然而，这些新疗法可能仍需数年才能问世，且拒绝接种疫苗者是否会接受治疗尚不确定。受南卡罗来纳州和犹他州大规模疫情推动，截至7月，美国今年麻疹病例数已超过去年全
Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease.
But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it’s even more uncertain if those who refuse vaccines would take such treatments.
Fueled by large outbreaks in South Carolina and Utah, the US had already surpassed last year’s 2,289 measles cases, and it’s only July. For comparison, there were just 285 cases in all of 2024.
转载信息
评论 (0)
暂无评论，来留下第一条评论吧